As the flu season gets underway over the next few weeks, public
health officials have been preparing for a unique set of challenges.
Some people are still looking for a last-minute flu shot due to delays
in immunization shipments from two manufacturers, and those experiencing
fever, aches, and fatigue from the flu may be more likely to head to
the emergency room this year due to concerns about the Ebola virus,
which causes similar symptoms.
“I’m speculating, but there’s no
doubt in my mind that more people will be hitting the emergency
departments this flu season suspecting that they or someone close to
them has Ebola,” said Dr. Eugene Litvak, president and CEO of the
Boston-based non-profit Institute for Healthcare Optimization.
Some people who normally don’t get a flu shot — only 53 percent of
Massachusetts residents were immunized last year — may seek one out this
year spurred by fears of false alarms concerning Ebola. “Friends have
told me they’re going to get vaccinated this year because of their Ebola
fears,” Litvak said, often worried that they’ll be stigmatized by
friends and co-workers if they come down with Ebola-like symptoms.
Dr.
Benjamin Kruskal, chief of infectious disease at Harvard Vanguard
Medical Associates, said he’s heard “occasional comments” from patients
asking about flu vaccinations in the context of Ebola, though he’s not
certain this led to an uptick in the seasonal immunization.
(Harvard
Vanguard made headlines last month for sending a patient suspected of
having Ebola to Beth Israel Deaconess Medical Center in Boston; the
patient, who had recently traveled to Liberia, was not found to be infected with the virus.)
Complicating matters, immunization shipments were delayed by two of
the biggest manufacturers, which left physician offices, clinics, and
pharmacies with a smaller supply during September and October, a peak
time for administering the vaccine.
Sanofi Pasteur, which plans to
fill orders for 65 million doses of Fluzone influenza vaccines this
year, said in a statement that it informed customers about delayed
shipments including its quadrivalent vaccine, containing four strains of
viruses, and trivalent vaccine, which contains three strains. “We
shipped the majority of doses in October but some of our doses will
continue to ship into November,” the statement said.
GSK, which
also manufacturers flu vaccine, attributed its two- to six-week delay in
shipments to “production difficulties” experienced at one of its
facilites in Quebec. “Vaccines manufacturing is an inherently complex
undertaking,” said GSK spokesperson Robert Perry. “When batches fail
quality-assurance tests at any stage of the process, we discard them and
essentially start over.”
He added that most of the vaccine doses that were pre-ordered months ago have been shipped or delivered.
“It
was a bit of a hiccup in our practice,” Kruskal said. “Normally we do
most of our immunizations in early October, but this year we had to push
them to the end of the month.”
The Boston Public Health
Commission received complaints from a handful of providers about vaccine
shortages. “A few places had a little trouble getting it but they have
plenty now,” said Dr. Anita Barry, director of the Infectious Disease
Bureau at the city health department.
But places may not have all
of the varieties of flu vaccines that consumers may request such as a
high-dose shot that appears to be more effective in seniors and a nasal
spray containing a live attenuated form of the virus that the Centers for Disease Control and Prevention recommends for children ages two to eight years old.
Target
pharmacies in the Boston area have dwindling supplies of Sanofi
Pasteur’s high-dose Fluzone vaccine and were alerted last week by the
manufacturer that they won’t be able to supply any more for the season.
“We have a few doses left,” said Hannah Lupinacci, pharmacy manager at
the Boston South Bay Target store, “but we’re running out of our
inventory.”
The pharmacy typically gets flu vaccine shipments
through January and often experiences a surge in customers coming in for
flu shots after the season gets underway in December, she added.
An August study published in the New England Journal of Medicine
found that the high-dose flu shot is 24 percent more effective at
preventing flu in people over age 65 compared to the standard-dose shot,
but Barry said seniors should not skip their vaccination this year if
they can’t get the higher dose.
“The CDC hasn’t recommended a
preference for high dose over regular dose for seniors,” Barry said.
“It’s far more important to get vaccinated with any available
immunization than to delay past the start of flu season.”
No comments: